Northern Trust Corporation Common Stock vs TG Therapeutics Inc — how do they compare? Northern Trust Corporation Common Stock trades at $162.48 (market cap $30.63B), while TG Therapeutics Inc trades at $54.41 (market cap $8.32B). The key difference: Northern Trust Corporation Common Stock is far larger — about 3.7× TG Therapeutics Inc's market cap, and Northern Trust Corporation Common Stock pays a 1.96% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Northern Trust Corporation Common Stock for 0 Days and TG Therapeutics Inc for 16 Days on average.
| NTRS | TGTX | |
|---|---|---|
Market Cap | $30.63B | $8.32B |
Volume | 964,550 | 1,001,204 |
Sector | Financials | Health |
52-Week High | $191.47 | $59.06 |
52-Week Low | $122.72 | $26.94 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | -$5.35B | $8.52B |
Dividend Yield | 1.96% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TG Therapeutics trades at $54.34, down 1.68% today, with a bullish technical outlook supported by moving averages. The company shows strong profitability with 55.22% net income margin and 100.28% ROE, though recent quarters saw EPS misses. Revenue guidance for 2026 is raised to $950M for BRIUMVI, with institutional buying interest from major banks. A shareholder investigation by Kuehn Law presents legal overhang.
Outlook remains positive given analyst consensus target of $80.50 (48% upside) and buyout speculation. Key risks include ongoing legal scrutiny and reliance on BRIUMVI's market share growth. The stock offers growth potential but requires monitoring of legal developments and competitive pressures in the MS treatment space.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Northern Trust Corporation is a financial holding company that provides asset servicing, asset management, wealth management, and banking services through its Asset Servicing and Wealth Management segments. It serves corporations, institutions, and affluent individuals across US and international markets.
Read more on NTRS →TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →